JP2016510006A - 癌治療のための使用 - Google Patents
癌治療のための使用 Download PDFInfo
- Publication number
- JP2016510006A JP2016510006A JP2015559400A JP2015559400A JP2016510006A JP 2016510006 A JP2016510006 A JP 2016510006A JP 2015559400 A JP2015559400 A JP 2015559400A JP 2015559400 A JP2015559400 A JP 2015559400A JP 2016510006 A JP2016510006 A JP 2016510006A
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- amino acid
- ferrous
- tumor
- chelate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 45
- 201000011510 cancer Diseases 0.000 title claims abstract description 29
- 238000011282 treatment Methods 0.000 title claims abstract description 9
- 239000013522 chelant Substances 0.000 claims abstract description 59
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 57
- 150000001413 amino acids Chemical class 0.000 claims abstract description 51
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 claims abstract description 46
- -1 ferrous amino acid Chemical class 0.000 claims abstract description 29
- 230000009920 chelation Effects 0.000 claims abstract description 6
- 239000003937 drug carrier Substances 0.000 claims abstract description 5
- 238000004519 manufacturing process Methods 0.000 claims abstract description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 34
- 208000014018 liver neoplasm Diseases 0.000 claims description 23
- 208000020816 lung neoplasm Diseases 0.000 claims description 19
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 18
- 229910052742 iron Inorganic materials 0.000 claims description 18
- 201000005202 lung cancer Diseases 0.000 claims description 18
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 14
- 201000007270 liver cancer Diseases 0.000 claims description 13
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 claims description 11
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 9
- 235000003891 ferrous sulphate Nutrition 0.000 claims description 8
- 239000011790 ferrous sulphate Substances 0.000 claims description 8
- 229910000359 iron(II) sulfate Inorganic materials 0.000 claims description 8
- 239000004471 Glycine Substances 0.000 claims description 7
- 239000003638 chemical reducing agent Substances 0.000 claims description 7
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 7
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 6
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims description 6
- 208000029742 colonic neoplasm Diseases 0.000 claims description 6
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 6
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 6
- 206010009944 Colon cancer Diseases 0.000 claims description 5
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 5
- 206010003571 Astrocytoma Diseases 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 4
- 201000010881 cervical cancer Diseases 0.000 claims description 4
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 3
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims description 3
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 3
- 235000011054 acetic acid Nutrition 0.000 claims description 3
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 3
- 235000010323 ascorbic acid Nutrition 0.000 claims description 3
- 239000011668 ascorbic acid Substances 0.000 claims description 3
- 229960005070 ascorbic acid Drugs 0.000 claims description 3
- 235000015165 citric acid Nutrition 0.000 claims description 3
- 229960002089 ferrous chloride Drugs 0.000 claims description 3
- 206010017758 gastric cancer Diseases 0.000 claims description 3
- NMCUIPGRVMDVDB-UHFFFAOYSA-L iron dichloride Chemical compound Cl[Fe]Cl NMCUIPGRVMDVDB-UHFFFAOYSA-L 0.000 claims description 3
- ATEAWHILRRXHPW-UHFFFAOYSA-J iron(2+);phosphonato phosphate Chemical compound [Fe+2].[Fe+2].[O-]P([O-])(=O)OP([O-])([O-])=O ATEAWHILRRXHPW-UHFFFAOYSA-J 0.000 claims description 3
- 239000004310 lactic acid Substances 0.000 claims description 3
- 235000014655 lactic acid Nutrition 0.000 claims description 3
- 239000001630 malic acid Substances 0.000 claims description 3
- 235000011090 malic acid Nutrition 0.000 claims description 3
- 235000019260 propionic acid Nutrition 0.000 claims description 3
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims description 3
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 3
- 201000011549 stomach cancer Diseases 0.000 claims description 3
- 239000001384 succinic acid Substances 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 206010061424 Anal cancer Diseases 0.000 claims description 2
- 208000007860 Anus Neoplasms Diseases 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 208000006274 Brain Stem Neoplasms Diseases 0.000 claims description 2
- 206010072960 Chest wall tumour Diseases 0.000 claims description 2
- 208000009798 Craniopharyngioma Diseases 0.000 claims description 2
- 206010014733 Endometrial cancer Diseases 0.000 claims description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 2
- 206010014967 Ependymoma Diseases 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims description 2
- 206010073069 Hepatic cancer Diseases 0.000 claims description 2
- 206010021042 Hypopharyngeal cancer Diseases 0.000 claims description 2
- 206010056305 Hypopharyngeal neoplasm Diseases 0.000 claims description 2
- 206010023825 Laryngeal cancer Diseases 0.000 claims description 2
- 208000004059 Male Breast Neoplasms Diseases 0.000 claims description 2
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
- 206010031096 Oropharyngeal cancer Diseases 0.000 claims description 2
- 206010057444 Oropharyngeal neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010061336 Pelvic neoplasm Diseases 0.000 claims description 2
- 208000007913 Pituitary Neoplasms Diseases 0.000 claims description 2
- 201000005746 Pituitary adenoma Diseases 0.000 claims description 2
- 206010061538 Pituitary tumour benign Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 201000011165 anus cancer Diseases 0.000 claims description 2
- 201000009036 biliary tract cancer Diseases 0.000 claims description 2
- 208000020790 biliary tract neoplasm Diseases 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- 201000010175 gallbladder cancer Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 201000006866 hypopharynx cancer Diseases 0.000 claims description 2
- 206010023841 laryngeal neoplasm Diseases 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 201000003175 male breast cancer Diseases 0.000 claims description 2
- 208000010907 male breast carcinoma Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 201000000349 mediastinal cancer Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 206010027191 meningioma Diseases 0.000 claims description 2
- 208000018223 neoplasm of chest wall Diseases 0.000 claims description 2
- 208000018280 neoplasm of mediastinum Diseases 0.000 claims description 2
- 201000006958 oropharynx cancer Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 208000021310 pituitary gland adenoma Diseases 0.000 claims description 2
- 208000016800 primary central nervous system lymphoma Diseases 0.000 claims description 2
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims description 2
- 201000000849 skin cancer Diseases 0.000 claims description 2
- 208000014680 small intestine neoplasm Diseases 0.000 claims description 2
- 239000000243 solution Substances 0.000 claims description 2
- 208000008732 thymoma Diseases 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 208000025444 tumor of salivary gland Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 208000037965 uterine sarcoma Diseases 0.000 claims description 2
- 210000001672 ovary Anatomy 0.000 claims 1
- 230000008859 change Effects 0.000 abstract description 3
- 210000002784 stomach Anatomy 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 28
- 238000011580 nude mouse model Methods 0.000 description 16
- 206010019695 Hepatic neoplasm Diseases 0.000 description 10
- 241000699660 Mus musculus Species 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 238000011579 SCID mouse model Methods 0.000 description 8
- MECJLZIFMOMXPW-UHFFFAOYSA-L 2-azanidylacetate iron(4+) Chemical compound O=C1CN[Fe]2(NCC(=O)O2)O1 MECJLZIFMOMXPW-UHFFFAOYSA-L 0.000 description 7
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 208000009956 adenocarcinoma Diseases 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 208000037841 lung tumor Diseases 0.000 description 4
- 208000000649 small cell carcinoma Diseases 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 229910000358 iron sulfate Inorganic materials 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 206010041823 squamous cell carcinoma Diseases 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000002302 brachial artery Anatomy 0.000 description 2
- 239000012830 cancer therapeutic Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000003978 infusion fluid Substances 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 208000003849 large cell carcinoma Diseases 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 210000002751 lymph Anatomy 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 description 1
- TZXKOCQBRNJULO-UHFFFAOYSA-N Ferriprox Chemical compound CC1=C(O)C(=O)C=CN1C TZXKOCQBRNJULO-UHFFFAOYSA-N 0.000 description 1
- 230000035519 G0 Phase Effects 0.000 description 1
- 230000010190 G1 phase Effects 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- QQUWFXMXRVAVCX-UHFFFAOYSA-N N-[(2-hydroxynaphthalen-1-yl)methylideneamino]benzamide Chemical compound OC1=CC=C2C=CC=CC2=C1C=NNC(=O)C1=CC=CC=C1 QQUWFXMXRVAVCX-UHFFFAOYSA-N 0.000 description 1
- UBQYURCVBFRUQT-UHFFFAOYSA-N N-benzoyl-Ferrioxamine B Chemical compound CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN UBQYURCVBFRUQT-UHFFFAOYSA-N 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 102000000505 Ribonucleotide Reductases Human genes 0.000 description 1
- 108010041388 Ribonucleotide Reductases Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001644 anti-hepatocarcinoma Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 229960004191 artemisinin Drugs 0.000 description 1
- BLUAFEHZUWYNDE-NNWCWBAJSA-N artemisinin Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2OC(=O)[C@@H]4C BLUAFEHZUWYNDE-NNWCWBAJSA-N 0.000 description 1
- 229930101531 artemisinin Natural products 0.000 description 1
- 229960002521 artenimol Drugs 0.000 description 1
- BJDCWCLMFKKGEE-ISOSDAIHSA-N artenimol Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2O[C@H](O)[C@@H]4C BJDCWCLMFKKGEE-ISOSDAIHSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- OEUUFNIKLCFNLN-LLVKDONJSA-N chembl432481 Chemical compound OC(=O)[C@@]1(C)CSC(C=2C(=CC(O)=CC=2)O)=N1 OEUUFNIKLCFNLN-LLVKDONJSA-N 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 229960003266 deferiprone Drugs 0.000 description 1
- 229960000958 deferoxamine Drugs 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 229930016266 dihydroartemisinin Natural products 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 108010045676 holotransferrin Proteins 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 150000002506 iron compounds Chemical class 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000002638 palliative care Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/295—Iron group metal compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
アミノ酸第一鉄キレートを含む医薬組成物を次のように調製した。先ず、硫酸鉄とグリシン(純度:98パーセント以上)とを1:1.3の重量比で、60℃ないし90℃で混合し、8時間ないし48時間加熱して、アミノ酸第一鉄キレートを含む組成物を得た。その際前記アミノ酸第一鉄キレートの第一鉄とアミノ酸とのキレート化比は1:1ないし1:4の間であり、アミノ酸第一鉄キレートを含む医薬組成物の濃度を0.1μg/μl、0.3μg/μl、1μg/μlまたは3μg/μlに調製した。
10%ウシ胎仔血清(FBS)、1%ペニシリン(100U/mL)−ストレプトマイシン(100g/mL)、1%グルタミン(200mM)を含むDMEM培地に、37℃、5%CO2においてA549細胞を播種し、二次培養のための約70%ないし80%の細胞粘着を得た。
SK Hepl細胞を、10%ウシ胎仔血清(FBS)、1%非必須アミノ酸(NEAA)、1%ペニシリン(100U/mL)−ストレプトマイシン(100g/mL)を含むDMEM培地に播種し、37℃、5%CO2で3〜4日間二次培養を1回行った。
調製例1から得られたアミノ酸第一鉄キレートを含む医薬組成物0.1μg/μl、0.3μg/μlまたは1μg/μlを、齢5〜6週のBALB/c nu/nuマウス(台湾のNational Laboratory Animal Centerから購入)に、それぞれ0.4mg/kg/日、1.2mg/kg/日または4mg/kg/日の量を、対照群には滅菌水を、それぞれ7日間投与した。調製例2から得られた1×107細胞/mL(100μl)のA549細胞をそれぞれ各ヌードマウスの後肢近くの上腕動脈の皮下に注射した。その後7日ごとに腫瘍のサイズと量をノギスで測定した。各ヌードマウスを6週間後に殺した。
腫瘍の量を次式により算出した。
(a×b2)/2(mm3)
[式中「a」は腫瘍の最も長い直径、「b」は、最も短い直径である。]
図4に示すように、対照群の生存率は4週間で75%であった。それにもかかわらず、SCIDマウスの生存率は、アミノ酸第一鉄キレートを含む医薬組成物4mg/kg/日を4週間投与することによって、100%に維持された。こうして、アミノ酸第一鉄キレートを含む医薬組成物の投与はSCIDマウスの生存率を高めることができた。
ヌードマウスを5群に分け、対照群には燐酸緩衝食塩液(PBS)を、第一群にはアミノ酸第一鉄キレートを含む医薬組成物1.2mg/kg/日を、第二群にはアミノ酸第一鉄キレートを含む医薬組成物12mg/kg/日を、第三群にはFerrochel(登録商標)(Albion Co.,Ltd.から購入)1.2mg/kg/日を、第四群には硫酸第一鉄(無機鉄)1.2mg/kg/日を、それぞれ7日間投与した。それから調製例2から得られた1×107細胞/mL(100μl)のA549細胞を各ヌードマウスの後肢近くの上腕動脈の皮下にそれぞれ注射した。その後、腫瘍のサイズおよび量を7日ごとにノギスで測定し、各ヌードマウスを6週間後に殺した。
Claims (13)
- 癌治療のための医薬組成物の製造におけるアミノ酸第一鉄キレートの使用であって、前記医薬組成物は、治療的有効量のアミノ酸第一鉄キレートと、薬物学的に容認し得る担体とを含んでなる使用。
- 前記アミノ酸第一鉄キレートの第一鉄とアミノ酸とのキレート化比が1:1と1:4との間にある請求項1に記載の使用。
- 前記アミノ酸第一鉄キレートの第一鉄とアミノ酸とのキレート化比が1:1.5と1:2.5との間にある請求項1に記載の使用。
- アミノ酸第一鉄キレートの治療的有効量が0.2mg/kg/日と15mg/kg/日との間にある請求項1に記載の使用。
- アミノ酸第一鉄キレートの治療的有効量が0.4mg/kg/日と12mg/kg/日との間にある請求項1記載の使用。
- アミノ酸第一鉄キレ−トの治療的有効量を調製するために、無機鉄とアミノ酸とを60℃ないし90℃で混合し、8時間ないし48時間加熱して、アミノ酸第一鉄キレートを含む組成物を得、無機鉄とアミノ酸との比が1:1.2と1:1.5との間にある請求項1に記載の使用。
- 無機鉄が硫酸第一鉄、塩化第一鉄またはピロ燐酸第一鉄であり、アミノ酸がグリシンである請求項6に記載の使用。
- アミノ酸第一鉄を含む前記医薬組成物が還元剤を含み、前記還元剤はアスコルビン酸、クエン酸、酢酸、プロピオン酸、酪酸、乳酸、リンゴ酸、スルホン酸、またはコハク酸である請求項6に記載の使用。
- 前記医薬組成物が経腸または非経口投与型である請求項1に記載の使用。
- 経腸投与型が経口投与型であり、経口投与型は溶液、懸濁液、錠剤またはカプセルである請求項9に記載の使用。
- 前記癌がメラノーマ、肝臓癌、結腸癌、肺癌、胃癌、食道癌、乳癌、前立腺癌、および白血病である請求項1に記載の使用。
- 前記癌が脳腫瘍、軽度の星状細胞腫、重度の星状細胞腫、下垂体腺腫、髄膜腫、CNSリンパ腫、乏突起細胞腫、頭蓋咽頭腫、上衣細胞腫、脳幹腫瘍、頭部および頸部腫瘍、喉頭癌、口咽頭癌、鼻咽頭腫瘍、唾液腺腫瘍、下咽頭癌、甲状腺癌、口腔腫瘍、胸壁腫瘍、小細胞性肺癌、非小細胞性肺癌(NSCLC)、胸腺腫、縦隔腫瘍、男性乳癌、腹部−骨盤腫瘍、ヘパトーマ、肝臓腺癌、胆嚢癌、胆道癌、膵臓癌、小腸腫瘍、大腸腫瘍、肛門癌、膀胱癌、腎細胞癌、子宮頸癌、子宮内膜癌、卵巣癌、子宮肉腫、および皮膚癌である請求項1に記載の使用。
- 前記癌が肝臓癌または肺癌である請求項1に記載の使用。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2013/001043 WO2015032011A1 (zh) | 2013-09-05 | 2013-09-05 | 含有亚铁氨基酸螯合物的组合物在制备抗癌症的药物中的用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2016510006A true JP2016510006A (ja) | 2016-04-04 |
JP5973684B2 JP5973684B2 (ja) | 2016-08-23 |
Family
ID=52627663
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015559400A Expired - Fee Related JP5973684B2 (ja) | 2013-09-05 | 2013-09-05 | 癌治療のための使用 |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP3042652B1 (ja) |
JP (1) | JP5973684B2 (ja) |
CN (1) | CN104955452B (ja) |
AU (1) | AU2013400082B2 (ja) |
CA (1) | CA2898771C (ja) |
WO (1) | WO2015032011A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2019519603A (ja) * | 2016-05-26 | 2019-07-11 | 普惠▲徳▼生技股▲分▼有限公司 | 乳酸を減少させるために使用する第一鉄アミノ酸キレートを含む組成物 |
JP2021511358A (ja) * | 2018-12-20 | 2021-05-06 | 普惠徳生技股▲ふん▼有限公司 | 第一鉄アミノ酸粒子を含む組成物、および膵臓関連疾患の治療または改善のための薬剤製造におけるその組成物の使用 |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI645848B (zh) * | 2016-12-02 | 2019-01-01 | 普惠德生技股份有限公司 | Use of a composition containing a ferrous amino acid chelate compound for the manufacture of a medicament for preventing cancer metastasis |
US20190365697A1 (en) * | 2017-02-17 | 2019-12-05 | Profeat Biotechnology Co., Ltd. | Method for Treating Liver Dysfunction |
WO2019127295A1 (zh) * | 2017-12-29 | 2019-07-04 | 普惠德生技股份有限公司 | 含有亚铁氨基酸螯合物的组合物用于制造抑制血管新生的医药品的用途 |
TWI732164B (zh) * | 2018-03-06 | 2021-07-01 | 普惠德生技股份有限公司 | 經燒結的胺基酸亞鐵粒子及其抗病毒的用途 |
TWI710370B (zh) * | 2018-12-20 | 2020-11-21 | 普惠德生技股份有限公司 | 含有亞鐵胺基酸螯合物粒子的組合物用於製備治療或減緩阿茲海默症或帕金森氏症的醫藥品的用途 |
TWI695719B (zh) * | 2018-12-20 | 2020-06-11 | 普惠德生技股份有限公司 | 含有亞鐵胺基酸粒子的組合物及其用於製造治療或改善胰臟相關疾病的醫藥品的用途 |
CN112168843A (zh) * | 2019-07-05 | 2021-01-05 | 普惠德生技股份有限公司 | 经烧结的纳米粒子及其抗病毒的用途 |
US20230012448A1 (en) * | 2021-06-30 | 2023-01-12 | Getwing Biotechnology Medical Co., Ltd | Methods for alleviating kidney disease and fibrosis of organ |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003042404A2 (en) * | 2001-11-13 | 2003-05-22 | Sirbasku David A | Breast cancer eradication program |
JP2008525445A (ja) * | 2004-12-22 | 2008-07-17 | ドラッグテック コーポレイション | 鉄吸収増進のための方法および組成物 |
JP2011016753A (ja) * | 2009-07-08 | 2011-01-27 | Sbi Alapromo Co Ltd | 5−アミノレブリン酸若しくはその誘導体、又はそれらの塩を有効成分とするがんの予防・改善剤 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2041M (fr) * | 1962-04-17 | 1963-09-30 | Andre Anselme Marie | Composition thérapeutique a propriétés cytotoxiques a base d'acide ascorbique et d'ions métalliques. |
US5578637A (en) * | 1995-05-03 | 1996-11-26 | University Of Washington | Methods of inhibition or killing cancer cells using an endoperoxide |
EP1658844A1 (en) * | 2004-10-19 | 2006-05-24 | Gerold Schuler | Use of artemisinin derivatives in the manufacture of a medicament for the treatment of melanoma |
US20090035385A1 (en) * | 2004-12-22 | 2009-02-05 | Drugtech Corporation | Compositions including iron |
JP2010504968A (ja) * | 2006-09-28 | 2010-02-18 | メルク エンド カムパニー インコーポレーテッド | Hdac阻害剤とキレート化可能な金属化合物を含んでなる医薬組成物、及び金属−hdac阻害剤キレート錯体 |
-
2013
- 2013-09-05 JP JP2015559400A patent/JP5973684B2/ja not_active Expired - Fee Related
- 2013-09-05 CN CN201380071525.8A patent/CN104955452B/zh not_active Expired - Fee Related
- 2013-09-05 WO PCT/CN2013/001043 patent/WO2015032011A1/zh active Application Filing
- 2013-09-05 AU AU2013400082A patent/AU2013400082B2/en not_active Ceased
- 2013-09-05 EP EP13893164.7A patent/EP3042652B1/en not_active Not-in-force
- 2013-09-05 CA CA2898771A patent/CA2898771C/en not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003042404A2 (en) * | 2001-11-13 | 2003-05-22 | Sirbasku David A | Breast cancer eradication program |
JP2008525445A (ja) * | 2004-12-22 | 2008-07-17 | ドラッグテック コーポレイション | 鉄吸収増進のための方法および組成物 |
JP2011016753A (ja) * | 2009-07-08 | 2011-01-27 | Sbi Alapromo Co Ltd | 5−アミノレブリン酸若しくはその誘導体、又はそれらの塩を有効成分とするがんの予防・改善剤 |
Non-Patent Citations (2)
Title |
---|
JPN6016024145; Biomedicine & Pharmacotherapy Vol.66, No.6, 2012, p.414-418 * |
JPN6016024148; Journal of Agricultural and Food Chemistry Vol.52, No.26, 2004, p.8132-8136 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2019519603A (ja) * | 2016-05-26 | 2019-07-11 | 普惠▲徳▼生技股▲分▼有限公司 | 乳酸を減少させるために使用する第一鉄アミノ酸キレートを含む組成物 |
JP2021511358A (ja) * | 2018-12-20 | 2021-05-06 | 普惠徳生技股▲ふん▼有限公司 | 第一鉄アミノ酸粒子を含む組成物、および膵臓関連疾患の治療または改善のための薬剤製造におけるその組成物の使用 |
JP6998087B2 (ja) | 2018-12-20 | 2022-02-04 | 普惠徳生技股▲ふん▼有限公司 | 第一鉄アミノ酸粒子を含む組成物、およびその組成物を含む、膵臓関連疾患の治療または改善のための薬剤 |
Also Published As
Publication number | Publication date |
---|---|
EP3042652A1 (en) | 2016-07-13 |
AU2013400082A1 (en) | 2015-08-06 |
CN104955452B (zh) | 2017-06-09 |
EP3042652A4 (en) | 2017-04-12 |
WO2015032011A1 (zh) | 2015-03-12 |
JP5973684B2 (ja) | 2016-08-23 |
CA2898771A1 (en) | 2015-03-12 |
CN104955452A (zh) | 2015-09-30 |
AU2013400082B2 (en) | 2016-01-28 |
EP3042652B1 (en) | 2018-08-29 |
CA2898771C (en) | 2017-01-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5973684B2 (ja) | 癌治療のための使用 | |
AU2015335375B2 (en) | Use of azelnidipine in preparing medicinal composition for treating cancers | |
US10702494B2 (en) | Method for cancer treatment | |
Chen et al. | Expanding the use of arsenic trioxide: leukemias and beyond | |
JP5289060B2 (ja) | Parpインヒビターとの組合せ療法 | |
JP5898074B2 (ja) | キナーゼ阻害作用を有する化合物の併用による抗腫瘍剤 | |
JP2014515373A5 (ja) | ||
JP6401317B2 (ja) | がんを治療するためのシステム、方法、および製剤 | |
JP4569106B2 (ja) | 臓器線維化抑制剤 | |
Zhu et al. | A traditional prescription comprising Astragali Radix and Schisandra chinensis Fructus induces apoptosis and protective autophagy in hepatocellular carcinoma cells | |
WO2014047782A1 (zh) | 含有白藜芦醇及白藜芦醇类衍生物和Bcl-2抑制剂的药物组合物及其应用 | |
JP2023065622A (ja) | 重度腎機能障害を有する癌患者に対する治療方法 | |
CN114948938B (zh) | 白术内酯i在制备预防和/或治疗宫颈癌的药物中的用途 | |
TW202320758A (zh) | 組合 | |
US20220409582A1 (en) | Combination therapies comprising panobinostat for the treatment of cholangiocarcinoma | |
Di Desidero et al. | Metronomic chemotherapy for triple negative breast cancer? | |
CN102319260A (zh) | 顺铂联合伊曲康唑异构体在制备治疗肺癌药物中的应用 | |
WO2015009879A1 (en) | Compositions for modulating nrf2-are activity and their methods of use | |
JP2019525924A (ja) | がんを処置するための併用療法 | |
WO2021196335A1 (zh) | Pyr3的用途 | |
WO2010032436A1 (ja) | 4-[[3,5-ビス(トリメチルシリル)ベンゾイル]アミノ]安息香酸を含有する抗腫瘍剤 | |
WO2023109741A1 (zh) | 一种治疗癌症的药物组合物 | |
WO2020045461A1 (ja) | ピラゾロ[3,4-d]ピリミジン化合物を有効成分とする治療剤 | |
Hiramatsu et al. | Growth‐inhibitory Effects of N, N‐Diethyl‐2‐[4‐(phenylmethyl) phenoxy]‐ethanamine‐HCl Combined with Cisplatin on Human Ovarian Cancer Cells Inoculated into Nude Mice | |
JP6702722B2 (ja) | 肝細胞がんの予防及び/又は治療剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20160628 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20160714 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5973684 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |